Feb 20 (Reuters) - AstraZeneca ( AZN ) will buy U.S.

biotech firm FibroGen's ( FGEN ) China unit for about $160

million, in its latest deal to boost its presence in the country

despite growing US-China trade tensions.

Fibrogen ( FGEN ) said the deal will give AstraZeneca ( AZN ) full rights to

its anemia drug roxadustat in China.

In December, AstraZeneca ( AZN ), which got about 12% of its 2024

sales from China, said it would buy Gracell Biotechnologies for

up to $1.2 billion in the country.

The dealmaking comes despite AstraZeneca ( AZN ) facing a string of

investigations into its executives and activities in the

country.

FibroGen ( FGEN ) said it expects the deal to close by mid-2025,

pending conditions, including a regulatory review in China.